Orchestra BioMed Holdings (OBIO) EBITDA (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has 6 years of EBITDA data on file, last reported at -$22.1 million in Q1 2026.

• On a quarterly basis, EBITDA fell 16.67% year-over-year to -$22.1 million in Q1 2026; TTM through Mar 2026 was -$55.0 million, a 20.11% increase from a year earlier, with the FY2025 full-year figure at -$51.8 million, up 19.43% from the prior year.
• EBITDA for Q1 2026 stood at -$22.1 million, down from $6.8 million in the prior quarter.
• Over the last five years, EBITDA for OBIO reached as high as $6.8 million in Q4 2025 and fell as low as -$22.1 million in Q1 2026.
• Historically, EBITDA has averaged -$13.1 million across 5 years, with a median of -$14.4 million in 2024.
• Across the five-year window, EBITDA tumbled 10577.39% in 2022 and surged 140.5% in 2025, its largest moves.
• Year by year, EBITDA stood at -$9.8 million in 2022, then fell by 26.99% to -$12.5 million in 2023, then tumbled by 33.62% to -$16.7 million in 2024, then jumped by 140.5% to $6.8 million in 2025, then slumped by 426.86% to -$22.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$22.1 million in Q1 2026, $6.8 million in Q4 2025, and -$20.3 million in Q3 2025.